Explore the words cloud of the KINETICfinder project. It provides you a very rough idea of what is the project "KINETICfinder" about.
The following table provides information about the project.
|Coordinator Country||Spain [ES]|
|Total cost||71˙429 €|
|EC max contribution||50˙000 € (70%)|
1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
|Duration (year-month-day)||from 2019-06-01 to 2019-11-30|
Take a look of project's partnership.
|1||ENZYMLOGIC SL||ES (TRES CANTOS MADRID)||coordinator||50˙000.00|
Bringing Bringing a new drug to the market costs 2,600 M€ and it takes 12 years. In addition, around 80% of drugs under research do not reach clinical trials (due to toxicity or lack of efficacy). ENZYMLOGIC was created with the aim of being a company in the niche of kinetic analysis. They have developed KINETICfinder: an experimental, robust, accurate and reproducible methodology that provides drug kinetic analyses in a massive way and at affordable cost, so it is possible to utilise it in early research stages, when thousands of drugs are involved. ENZYMLOGIC has been focused on providing auxiliar external analysis having pharmaceutical companies as customers. Nowadays, there are no comparable technologies capables of generating this amount of information with this level of processivity (number of drugs analysed at the same time). Currently, this analysis is extremely slow and costly, thus it is carried out in the final stages of the research, with just a small number of drugs. Otherwise, the number of different drugs they can analyse is 10 times higher and 10 times faster than other kinetic analysis (processivity). KINETICfinder can reduce the time and cost by 50% from the research phase of a new drug to the market phase. KINETICfinder already makes it possible to analyse 30 kinase targets (involved in cancer), and the next step is to work with GPCRs (neurodegenerative disorders, inflammation, pain, cardiovascular diseases and diabetes). 40% of the existing drugs are aimed at GPCRs. ENZYMLOGIC has obtained several prizes recognizing innovation and potential growth. The objective in phase I will be the validation of the use of KINETICfinder for working with GPCRs having as a base the previous work performed with kinases. To achieve this, the associated tasks shall be: validation of the method working with GPCRs having as a base the previous work performed with kinases, detailed market study & business plan elaboration and validation of commercialization strategy.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "KINETICFINDER" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (firstname.lastname@example.org) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "KINETICFINDER" are provided by the European Opendata Portal: CORDIS opendata.
Dyme gives its users complete control over their financial situation. The Dyme application provides insight into users’ spending and subscriptions, and lets users cancel, negotiate, or switch any contRead More
IOT and cloud computing for online medical analysis service platformRead More
Disruptive technology for the identification, quantification and prediction of the evolution of damages in civil engineering structures that increases safety while reducing maintenance costs.Read More